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Abstract
Background and Aim: Granulin-epithelin precursor (GEP) has previously been reported to control cancer growth, invasion,
chemo-resistance, and served as novel therapeutic target for cancer treatment. However, the nature and characteristics of
GEP interacting partner remain unclear. The present study aims to identify and characterize the novel predominant
interacting partner of GEP using co-immunoprecipitation and mass spectrometry.
Methods and Results: Specific anti-GEP monoclonal antibody was used to capture GEP and its interacting partner from the
protein extract of the liver cancer cells Hep3B. The precipitated proteins were analyzed by SDS-PAGE, followed by mass
spectrometry and the protein identity was demonstrated to be tropomyosin 3 (TPM3). The interaction has been validated in
additional cell models using anti-TPM3 antibody and immunoblot to confirm GEP as the interacting partner. GEP and TPM3
expressions were then examined by real-time quantitative RT-PCR in clinical samples, and their transcript levels were
significantly correlated. Elevated TPM3 levels were observed in liver cancer compared with the adjacent non-tumorous liver,
and patients with elevated TPM3 levels were shown to have poor recurrence-free survival. Protein expression of GEP and
TPM3 was observed only in the cytoplasm of liver cancer cells by immunohistochemical staining.
Conclusions: TPM3 is an interacting partner of GEP and may play an important role in hepatocarcinogenesis.
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Introduction
Hepatocellular carcinoma (HCC) is a malignant neoplasm of
hepatocytes and it accounts for more than 80% of primary liver
cancers [1–2]. HCC is a major global health problem. It shows
significant regional variations with a very high incidence rate in
Asia and Sub-Saharan Africa compared with the Western
countries, where there is also increasing incidence. In Hong
Kong, HCC is the fourth most common cancer and the mortality
rate ranks the third. The main etiological factors for HCC include
alcoholic cirrhosis, infection of hepatitis viruses B and C, chronic
exposure to aflatoxin B1 and haemochromatosis. In addition,
alpha-1-antitrypsin deficiency and Wilson’s disease are also
potential risk factors for HCC development. Although the curative
treatment for HCC is surgical resection or liver transplantation,
only a minority of HCCs are amenable to surgery as symptoms
attributable to HCC usually develop in the late stages of the
disease. Besides, most of the HCC patients have advanced
cirrhosis which leads to insufficient hepatic remnant and normal
liver function after liver resection and hence, surgical resection is
not applicable for many patients. Another concern is the high
recurrence rate after surgical resection. Fifty to eighty percent of
patients suffer disease recurrence, which could be intrahepatic
metastasis or multicentric occurrence, within five years after
resection. Chemotherapy is an alternative treatment of HCCs.
However, only marginal efficacy has been observed and severe
side effects are hurdle to the feasibility of chemotherapy [1–2].
Several important intracellular signaling pathways including the
mitogen-activated protein kinases comprising the ERK, JNK and
p38 have been recognized to be involved in hepatocarcinogenesis
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[3]. In addition, several growth factors and angiogenic factors such
as EGF and VEGF have been suggested to contribute to HCC [3].
However, the molecular pathogenesis of HCC has not been well
characterized yet. It is a major global health problem, and the
prognosis is dismal. The need for better understanding of the
cellular and molecular mechanisms of the disease is obvious and
crucial to disease prevention and management. Recently, the
advanced cDNA microarray technology has greatly facilitated the
genome-wide expression profiling in many complex diseases such
as cancers. Understanding the gene expression profiles in HCC
may provide new insights in identifying novel candidate bio-
markers for early diagnosis and discovery of therapeutic targets for
cancer treatment.
Our earlier cDNA microarray study revealed differential gene
expression patterns in HCC and non-tumor liver tissues [4–5].
Granulin-epithelin precursor (GEP) expression was observed in
over 70% of HCC [6]. Functional studies revealed that GEP
controlled cancer cells proliferation, invasion and chemo-resis-
tance [6–7]. We therefore investigated the potential of GEP as
a therapeutic target. Anti-GEP monoclonal antibodies were
developed and demonstrated to be able to inhibit the growth of
hepatoma cells but no effect on normal liver cells [8]. In nude mice
model transplanted with human HCC, dose-dependent inhibitory
effect was demonstrated with the anti-GEP monoclonal antibodies,
providing evidences that GEP is a therapeutic target for HCC
treatment [8]. GEP expression has also been reported in a number
of aggressive tumors, involved in various biological processes
including wound healing, murine fetal development, and mutation
associated with frontotemporal lobar dementia [9]. GEP has been
reported to interact with Tat proteins of Human Immunodefi-
ciency Virus (HIV), with COMP and TNF receptors in
chondrocyte [10–12]. Nonetheless, the GEP interacting part-
ners/receptors have yet to be identified in cancer cells [13–14].
To further understand the GEP signaling mechanism, the
present study aims to identify its novel predominant interacting
partners. Proteins that interact with GEP were examined using co-
immunoprecipitation and mass-spectrometry. The GEP interact-
ing protein had been further examined in additional cell lines and
clinical samples using western blot, immunohistochemistry and
real-time quantitative PCR.
Materials and Methods
Antibodies
Anti-GEP monoclonal antibody raised against the GEP
carboxyl-terminus was used for immunoprecipitation [8]. Anti-
bodies for TPM3 (polyclonal antibodies raised against the low
molecular weight isoform 2, Sigma-Aldrich, St. Louis, MO), anti-
mouse IgG and anti-rabbit IgG secondary antibodies (Dako,
Carpinteria, CA) were purchased.
Cell Lines
Two human liver cancer cell lines, Hep3B and HepG2
(American Type Culture Collection, ATCC, Manassas, VA), were
used in the immunoprecipitation experiments. Hep3B was derived
from an 8 years old juvenile patient, whereas HepG2 was derived
from a 15 years old adolescent patient. The two cell lines were
grown in AMEM medium containing 10% fetal bovine serum
(FBS) and L-glutamine supplement at 37uC in 5% CO2. GEP full-
length cDNA and anti-sense fragment construct were transfected
into the liver cancer cells to obtain stable transfectants for GEP
overexpression and GEP suppression, respectively. Stable clones
were selected by G418 as described previously [6]. Another two
cell lines Hela and NIH3T3 (ATCC) were used as references in
the immunoblotting experiments. HeLa was adenocarcinoma cells
derived from the cervix of a 31 years old patient, whereas NIH3T3
was mouse fibroblast cell line derived from the mouse embryo.
Clinical Samples
The studpy protocol was approved by the Institutional Review
Board of the University of Hong Kong/Hospital Authority Hong
Kong West Cluster (HKU/HA HKW IRB). Patients underwent
curative partial hepatectomy for HCC at Queen Mary Hospital,
Hong Kong, were recruited with written inform consent to the
study. Total RNA was extracted from snap frozen tissue specimens
for mRNA expression study using real-time quantitative PCR,
whereas formalin-fixed paraffin-embedded tissues were used for
histological and immunohistochemical studies.
Coimmuniprecipitation
Total cell lysates were obtained using NET buffer (50 mM Tris-
HCl pH7.5, 15 mM EDTA, 100 mM NaCl, 0.1% Triton X-100)
in the presence of complete protease inhibitor (Roche) and 1 mM
phenylmethylsulphonyl fluoride (USB, Cleveland, OH). Briefly,
cells were first washed by PBS and cell pellet was collected by
trypsinization. The cell pellet was washed using PBS and then NET
was added to resuspend the cells. The lysate was then incubated on
ice for 30minutes and followed by centrifugation at 14,000 x g for 20
minutes at 4uC. The supernatant was collected and the concentra-
tion of the total protein was determined using the BioRad DC
Protein Assay Kit (BioRad, Philadelphia, PA). A total of 400 mg
extracted protein lysate was used for each co-immunoprecipitation
reaction. The monoclonal anti-GEP antibody which is specific to
humanGEP was used to coimmunoprecipitate GEP and its binding
partners. Two control reactions, antibody alone and protein lysate
alone, were also included as reference to the non-specific binding of
unrelated proteins with the protein G-Sepharose. Two microgram
of monoclonal anti-GEP antibody was incubated with 400 mg total
protein lysate at 4uC with rotation overnight. For each reaction,
100 ml of protein G-Sepharose beads (Amersham Biosciences,
Piscataway, NJ) were washed with 500 ml NET buffer for 3 times.
Washed protein G-Sepharose beads were incubated with the
antibody-protein complexes at 4uC with rotation for 1 hour. After
incubation, the complexes were briefly centrifuged and supernatant
was discarded. The beads were washed with 500 ml ice-cold NET
buffer for 5 times to wash any unbounded proteins.
Identification of the Major Interacting Partner by SDS-
PAGE
The coimmunoprecipition product was then analysed by typical
one-dimensional SDS-PAGE. The immunocomplex-bound pro-
tein G-Sepharose beads were resuspended using 26protein buffer
(46Tris.CL/SDS, pH6.8, glycerol, bromophenol blue and b-
mercaptoethanol). Proteins were denatured at 95uC for 5 minutes.
The supernatant containing the proteins were separated under
denaturing condition on 10% SDS-PAGE gel and followed by
SimplyBlue (Invitrogen, Carlsbad, CA) staining which is a mass-
spectrometry compatible coomassie blue stain. The major
differential band observed in the co-immunoprecipitation reaction
but absent in the two control reactions (antibody alone and protein
lysate alone) were excised from the gel and further analyzed by
mass-spectrometry.
Protein Identification by Mass Spectrometry
The differential protein band was excised from stained gel, and
in-gel trypsin digestion was performed as previously described
[15]. The gel pieces were destained, reduced with 1.75% DTT,
TPM3 and GEP in HCC
PLoS ONE | www.plosone.org 2 July 2012 | Volume 7 | Issue 7 | e40324
TPM3 and GEP in HCC
PLoS ONE | www.plosone.org 3 July 2012 | Volume 7 | Issue 7 | e40324
alkylated with 350 mM iodoacetamide (IAA), and digested with
modified porcine trypsin overnight (sequencing grade, Promega,
Madison, WI). The tryptic peptides were harvested, cleaned up
with C18 ZipTips (Millipore Corp., Billerica, MA), and subjected
to MALDI-TOF/TOF MS (Ultraflex-III, Bruker Daltonics,
Bremen, Germany) with a-cyano 4-hydroxy cinnamic acid as
the matrix. The MS and MS/MS spectra were automatically
processed with the FlexAnalysis program (version 3.0, Bruker
Daltonics) with the default parameters. The MS spectrum data
were searched via the MASCOT search engine to obtain the
protein identity by undertaking the peptide mass fingerprinting
(PMF) approach and the MS/MS ion search approach. For the
search parameters, 1 missed cleavage in trypsin digestion was
allowed; partial oxidation of methionine, phosphorylation of
serine/threonine/tyrosine, and iodoacetamide modification of
cysteine residues were selected. The error tolerance values of the
parent peptides and the MS/MS ion masses were 50 ppm and
0.1 Da, respectively. For a gel spot, an identification result was
considered valid when both PMF and MS/MS ion search
identified the same protein as the statistically significant hit
(expectation value ,0.05) from the Swiss-Prot database, and MS/
MS ion search identified at least 2 tryptic peptides with sequences
from the same protein as the statistically significant hits.
Western Blotting
For protein expression on cell lines, aliquot of 20 mg total
protein lysate were separated in 10% SDS-PAGE gel [6,8].
Proteins were then electro-transferred onto polyvinylidene fluoride
membranes and subsequently incubated overnight at 4uC with
primary antibodies against GEP or TPM3. Detection was
performed by horseradish peroxidase-labelled secondary antibo-
dies with enhanced chemiluminescence (AP Biotech, Chalfont St.
Giles, UK).
Real-time Quantitative PCR
Real-time quantitative PCR was performed as described
previously [6]. Primers and probe for TPM3 were ready-made
reagents that recognized the low molecular weight isoforms 2 to 5
but not the high molecular weight isoform 1 (Pre-designed
TaqMan Gene Expression Assay, Applied Biosystems, Foster
City, CA). Primers and probe for GEP were GRN-forward (59-
CAA ATG GCC CAC CCA ACT GA-39), GRN-reverse (59-CCC
TGA GAC GGT AAA GAT GCA-39) and GRN-probe (59-6FAM
CCA CTG CTC TGC CGG CCA CTC MGBNFQ-39) [6].
Primer and probe reagents for control 18S were ready-made
reagents (Pre-designed TaqMan Assay Reagents, Applied Sys-
tems). The mRNA expressions of GEP and TPM3 were examined
in 44 pairs of HCC tissues and their paralleled adjacent non-tumor
liver tissues. The relative amount of GEP and TPM3 had been
normalized with control 18S for RNA amount variation and
calibrator for plate-to-plate variation. The mRNA expression was
presented as the relative fold change.
Immunohistochemical Staining
Protein expression of GEP and TPM3 were investigated by
immunohistochemical staining on formalin-fixed and paraffin-
embedded clinical specimens [6,8]. Monoclonal anti-GEP anti-
body at a dilution of 1:500 and polyclonal anti-TPM3 antibody at
a dilution of 1:100 was used in the staining. Immunohistochem-
istry was performed using the Dako Envision Plus System (Dako,
Carpinteria, CA) following manufacturer’s instruction. Briefly,
sections were deparaffinised with xylene and hydrated with
ethanol and then distilled water. Antigen retrieval was performed
by boiling in citrate buffer (pH 6) for 10 minutes. Endogenous
peroxidase was inactivated followed by primary antibody in-
cubation at room temperature and expression signal was detected
by incubation with horseradish peroxidase-conjugated secondary
antibody at room temperature. The brown stain was developed
with diaminobenzidine as the chromogen and the section was
counterstain with hematoxylin.
Results
Identification of TPM3 as a Predominant Binding Partner
of GEP
To identify the GEP interacting proteins, co-immunoprecipita-
tion was performed using the monoclonal anti-GEP antibody.
Liver cancer cells Hep3B expressed a higher GEP levels compared
to HepG2 cells, and both levels were significantly higher than
normal liver tissues. In order to increase the detection efficiency by
using GEP as the ligand, Hep3B cells transfected with GEP full-
length construct (Hep3B FL) were used for overexpression of GEP
protein. The predominant interacting partner was identified by
separating and comparing the immunoprecipitated proteins of
anti-GEP antibody and those of control setups (antibody alone and
protein lysate alone) by one-dimensional SDS-PAGE. An obvious
major differential band with the size at around 34 kDa was
observed only in the reaction lane but not in the control reaction
lanes (Figure 1). The major differential band was excised, in-gel
digested with trypsin and analyzed by MALDI-TOF/TOF MS.
Both peptide mass fingerprint (PMF) and MS/MS ion search
analyses identified the major differential band as tropomyosin 3
(TPM3, also named tropomyosin alpha-3 chain and located at
1q21.2). The representative MS spectra and matched masses to
peptides of corresponding protein were shown in Figure 1 and
Table 1. Tandem MS analysis of a tryptic peptide at m/z 1284.8
revealed an amino acid sequence of KLVIIEGDLER, which was
only present in all isoforms of TPM3, but not in any isoforms of
TPM1, TPM2 and TPM4 (Figure 1D, Figure S1).
Validation of the Interaction of GEP and TPM3
To confirm the results obtained from the co-immunoprecipita-
tion and mass spectrometry, the interaction between GEP and
TPM3 was validated by immunoprecipitation using anti-TPM3
antibody, then followed with immunoblot detection using anti-
GEP antibody in Hep3B FL and HepG2 FL. A band with
expected GEP size (90 kDa) was observed only on anti-TPM3
antibody-precipitated protein but not in the control reactions
Figure 1. Identification of TPM3 as the predominant binding partner of GEP. (A) SDS-PAGE analysis of co-immunoprecipitation reactions
using total protein lysate from liver cancer cells Hep3B and monoclonal anti-GEP antibody. M: Protein marker (Fermentus prestained protein marker);
Lane 1: Immunoprecipitation product of protein lysate and anti-GEP antibody; Lane 2: Protein lysate alone; Lane 3: Anti-GEP antibody alone. The
protein band indicated by the arrow was excised from the gel and the protein identity was examined by MS. (B) MALDI-TOF/TOF-MS analysis of the
tryptic peptides. The peptides matched to TPM3 were asterisked. (C) Protein sequence of TPM3 was shown, and matched peptides were underlined.
(D) An annotated representative tandem MS mass spectrum of a tryptic peptide (M/Z 1284.8) with the amino acid sequence identified as
KLVIIEGDLER.
doi:10.1371/journal.pone.0040324.g001
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(Figure 2 A–B). The data indicated that GEP was immunopre-
cipitated by anti-TPM3 antibody and therefore verified the
interaction of GEP and TPM3 proteins.
Expression of TPM3 was investigated on a panel of cell lines
(Figure 2 C, Figures S2 and S3). TPM3 protein expression levels
were shown to be correlated with the protein expression levels of
GEP in which elevated TPM3 expression was observed in Hep3B
FL and HepG2 FL cells (GEP overexpression), whereas decreased
level of TPM3 expression was observed in Hep3B AS cells
transfected with GEP-antisense fragment (GEP suppression)
(Figure 2 C). Nonetheless, suppression of TPM3 by siRNA
approach demonstrated insignificant effect on alterations of GEP
mRNA and protein levels, and GEP expression modulations
showed minimal effect on TPM3 mRNA levels (Figures S2 and S3,
Text S1). Further investigation would be warranted to delineate
the association between GEP and TPM3 protein levels.
Correlation of GEP and TPM3 in Clinical Specimens
Real-time quantitative RT-PCR was performed to investigate
the mRNA expression level of TPM3 in HCC and the paralleled
adjacent non-tumorous liver tissues. A total of 44 pairs of HCC
and non-tumor liver tissues were investigated. Elevated TPM3
levels were observed in tumor compared to non-tumor tissues (P
=0.001) (Figure 3A). The expression levels of GEP and TPM3
were significantly correlated (n = 88, Spearman’s r correlation
coefficient = 0.658, P,0.001) (Figure 3B). Increased GEP levels
were associated with cancer recurrence [6,7], thus the association
of TPM3 with recurrence-free survival was examined. The
patients were segregated into TPM3 high and low groups using
the TPM3 median level as the cutoff value. The median
recurrence-free survivals for TPM3-high and TPM3-low groups
were 8.0 and 52.0 months, respectively. Patients with elevated
TPM3 levels were shown to have poor recurrence-free survival
(log-rank test, P =0.0496) (Figure 3C).
Protein expression of TPM3 was investigated by immunohisto-
chemical staining, and TPM3 protein was observed only in tumor
tissues but not in the non-tumorous tissues (Figure 4 A–D). The
staining patterns of GEP and TPM3 were compared (Figure 4 E–
H). Similar expression patterns were observed in the serial sections
that stained for GEP and TPM3, and both proteins co-localized in
the cytoplasm of the HCC cells.
Discussion
Protein-protein interacting partners are traditionally identified
by undertaking the Western blot approach with the use of specific
antibodies. However, this type of approach is hypothesis-driven,
and therefore requires a ‘‘good guess’’ of the potential interacting
partners for choosing the specific antibodies to examine the
protein-protein binding. The Western blot approach, hence, is
usually not cost effective. Recent advances in proteomic technol-
ogies for identification of unknown proteins at low quantity have
allowed us to use an unbiased and non-hypothesis driven approach
to look for novel protein-protein interacting partners. In this study,
we aim to identify the novel predominant interacting proteins of
GEP in HCC. The first phase, identification phase, has been
examined with co-immunoprecipitation using anti-GEP antibody
to capture GEP and its interacting protein partners, followed with
comparative 1D SDS-PAGE analysis and mass spectrometry
analysis. Our result revealed an obvious differential protein band
as the putative predominant GEP interaction partner, which was
later shown to be TPM3. We subsequently confirmed their
interactions and cellular co-localizations by Western blot analysis
and histological examination in clinical specimens, respectively.
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Although we aimed to examine for the predominant binding
partner of GEP in the present study, other minor binding partners
of GEP may exist. Further studies for identifying the minor
binding partners using nano-LC/MS method are on-going in our
laboratories.
In the second phase of this study, validation phase, the
interaction between GEP and TPM3 has been investigated with
additional cell models, using anti-TPM3 antibody to capture
TPM3 and its binding partners, followed by immunoblot to
confirm the interaction of GEP with TPM3. Further investigation
on clinical specimen demonstrated GEP and TPM3 to be
overexpressed in HCC compared with non-tumor liver sample,
and the expression levels of GEP and TPM3 were significantly
correlated. Immunohistochemical staining also revealed that GEP
and TPM3 are co-localised in the cytoplasm of HCC cells. The
present study consolidated TPM3 as the interacting partner of
GEP.
Tropomyosin is an actin-binding protein which exists in both
muscle and non-muscle cells [16]. Function of tropomyosin has
been well established in muscle cells in which it plays a central role
in muscle contraction through regulating the cooperative binding
of actin to myosin in response to the calcium ion flux. However,
the role of tropomyosin remains unclear in non-muscle cells
although its principle role is to stabilize and modulate the function
of the actin filaments [17]. Tropomyosins belong to a multi-
isoform family. There are approximately 40 isoforms of tropomy-
osin identified in mammals [18–19]. Distinct isoforms are believed
to possess cell-type specific functions by binding to diverse actin
filaments and thereby confer regulation of the microfilaments in
different tissues [20]. hTM3 (a high molecular mass tropomyosin
isoform, also referred as the tropomyosin alpha-1 chain isoform 4
Figure 2. Association of TPM3 and GEP. (A–B) Protein-protein interaction of TPM3 and GEP was validated by immunoprecipitation using anti-
TPM3 antibody, followed with immunoblot detection using anti-GEP antibody in different cell lines (A) Hep3B and (B) HepG2 cells. (C) Positive
correlation of GEP and TPM3 on protein level. AS: Cells suppressed for GEP by transfection with anti-sense GEP fragment; FL: Cells overexpressed for
GEP by transfection with full-length (FL) GEP cDNA construct. Cells with overexpression of GEP showed elevated TPM3 levels, while suppression of
GEP showed decreased TPM3.
doi:10.1371/journal.pone.0040324.g002
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[21]), but not hTM5 (a low molecular mass tropomyosin isoform,
also referred as the TPM3 isoform 2 [22]), is involved in
intracellular granule movements in the rat kidney epithelial cells
[23]. In CHO cells, chimeric protein of hTM3 and hTM5 was
involved in multinucleation and cytokinetic defects [24]. It would
be important to differentiate the involvement of different isoforms.
Nonetheless, the current proteomic approach identified the tryptic
peptides (Figure 1) were conserved sequences common to TPM3
high and low molecular weight isoforms. Notably, the TPM3
antibodies (Figure 2 and 4) were raised against the TPM3 low
molecular weight isoform 2. For TPM3 transcript quantification
(Figure 3), the primer and probe set also recognized the low
molecular weight isoforms 2 to 5. The liver cancer cells and
clinical samples showed low/undetectable transcript levels of
TPM3 high molecular weight isoform 1 (data not shown).
Therefore, GEP should be associated with TPM3 low molecular
weight isoforms in liver cancer. However, the association of GEP
with TPM3 high molecular weight isoform in other cancer types
could not be excluded because these isoforms have significant
conserved sequences. Increased or decreased expression of
different tropomyosin isoforms have also been reported in
a number of human solid tumors [25–30], although the functional
significance of differential expression is unclear.
In the present study, we have demonstrated elevated expression
of TPM3 in HCC. Dysregulation of TPM3 has also been reported
in other human diseases. Missense mutation in the TPM3 has
been reported to be associated with autosomal nemaline myop-
athy, a disease characterized by the presence of muscle fibres in
the pathognomonic rod bodies [31–34]. In anaplastic large-cell
lymphoma, TPM3 is involved in hematopoietic tumorigenesis by
forming TPM3-ALK (anaplastic lymphoma kinase) fusion through
chromosome (1;2) translocation [35]. TPM3-ALK fusion gene is
further investigated to be involved in transformation, proliferation,
invasion and metastasis in anaplastic large-cell lymphoma [36].
Notably, chromosomal gain at 1q, 8q and 17q are frequently
detected in HCC [25]. These chromosomal regions may contain
important oncogenes or growth factors. TPM3 is located at the
region of chromosome 1q21.2. In a recent study examining the
HCC genetic aberrations using whole-genome array-CGH, TPM3
has been identified in the recurrent gain region on chromosome 1q
as important for HCC tumorigenesis [25]. Therefore, over-
expression of TPM3 would potentially be explained by gene
amplification rather than mutation or gene fusion mechanism.
In summary, we are the first group to demonstrate that TPM3 is
a predominant interacting partner of GEP in the cytoplasm of
HCC cells. Notably, TPM3 has been reported to control
migration, invasion and anchorage-independent growth of HCC
cells [37], and previously we have reported that GEP regulates
growth, invasion and anchorage-independent growth of HCC cells
[6]. As the current study demonstrated TPM3 as the cytoplasmic
interacting partner of GEP, thus the two molecules may act
together to control the invasion and anchorage-independent
growth ability of the HCC cells. Further studies to investigate
other TPM family members with GEP on their potential protein-
protein interactions would be warranted.
Figure 3. Over-expression of TPM3 and GEP mRNA levels in
liver cancer. (A) Elevated expressions of TPM3 were observed in liver
cancer (hepatocellular carcinoma, HCC) compared with the paralleled
adjacent non-tumor liver tissues (P =0.001, respectively). (B) Transcript
levels of GEP and TPM3 were significantly correlated (Spearman’s r
correlation coefficient = 0.658, P,0.001). (C) Kaplan-Meier recurrence-
free survival plot according to TPM3 levels (log-rank test, P = 0.0496).
Patients in the TPM3-high group showed poor recurrence-free survival
compared to TPM3-low group (median recurrence-free survivals 8.0 and
52.0 months, respectively).
doi:10.1371/journal.pone.0040324.g003
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Supporting Information
Figure S1 Comparison of the reference protein se-
quences of TPM1-4. Underlined regions were the MALDI-
TOF/TOF-MS analysis of the tryptic peptides matched to TPM3.
Mismatches were highlighted. The 5 isoforms of TPM3 are
conserved in the tryptic peptide regions. The 7 isoforms of TPM1,
the 2 isoforms of TPM2 and the 2 isoforms of TPM4 are
conserved in the tryptic peptide regions as shown in the reference
sequences.
(DOC)
Figure S2 Suppression of TPM3 by siRNA. Three different
siRNAs against TPM3 were transfected to Hep3B and HepG2
cells respectively. The three controls included the parental cells
only (c), cells incubated with lipofectamine only (lipo) and cells
mock-transfected with siRNA negative control (NC). TPM3
suppression by siRNAs decreased the TMP3 mRNA and protein
levels but showed insignificant effect on GEP levels.
(DOC)
Figure S3 Modulation of GEP levels. Suppression of GEP
was performed in Hep3B cells with high endogenous GEP levels.
Overexpression of GEP was performed in HepG2 cells with
relatively low endogenous GEP expression. GEP expression
modulations showed minimal effect on TPM3 mRNA levels.
(DOC)
Text S1 Supplementary Materials and Methods.
(DOC)
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